Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways
2014 · Cancer Immunology Immunotherapy · 152 citations
https://doi.org/10.1007/s00262-014-1610-3
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
306
Papers
4.7K
Citations
32
h-index
54
i10-index
Michael Robbins is an academic researcher from Princeton University. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & Psychotherapy Techniques and Applications & Immune Cell Function and Interaction. The author has an h-index of 32, co-authored 261 publications.
ORCID: 0000-0001-5012-0623https://doi.org/10.1007/s00262-014-1610-3
https://doi.org/10.4049/jimmunol.162.3.1270
Click to start Chat